Evidence map›Paper›PMID 26228524›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2016

Rasd2 Modulates Prefronto-Striatal Phenotypes in Humans and 'Schizophrenia-Like Behaviors' in Mice.

Daniela Vitucci, Annabella Di Giorgio, Francesco Napolitano, Barbara Pelosi, Giuseppe Blasi, Francesco Errico, Maria Teresa Attrotto, Barbara Gelao, Leonardo Fazio, Paolo Taurisano and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Multi-region mNature neuroscience · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. MiR-4763-3p targetingAging and disease · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Daniela VitucciCeinge Biotecnologie Avanzate, Naples, Italy.
Annabella Di GiorgioIstituto di Ricovero e Cura a Carattere Scientifico 'Casa Sollievo della Sofferenza', Foggia, Italy.
Francesco NapolitanoCeinge Biotecnologie Avanzate, Naples, Italy.
Barbara PelosiDepartment of Biology, Unit of Cell and Developmental Biology, University of Pisa, Pisa, Italy.
Giuseppe BlasiGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Francesco ErricoCeinge Biotecnologie Avanzate, Naples, Italy.
Maria Teresa AttrottoGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Barbara GelaoGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Leonardo FazioGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Paolo TaurisanoGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Anna Di MaioCeinge Biotecnologie Avanzate, Naples, Italy.
Valentina MarsiliCeinge Biotecnologie Avanzate, Naples, Italy.
Massimo PasqualettiDepartment of Biology, Unit of Cell and Developmental Biology, University of Pisa, Pisa, Italy.
Alessandro BertolinoGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
Alessandro UsielloCeinge Biotecnologie Avanzate, Naples, Italy.
Ceinge Biotecnologie Avanzate (Italy) · ITUniversity of Naples Federico II · ITCasa Sollievo della Sofferenza · ITItalian Institute of Technology · ITRoche (Switzerland) · CHUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rasd2 is a thyroid hormone target gene, which encodes for a GTP-binding protein enriched in the striatum where, among other functions, it modulates dopaminergic neurotransmission. Here we report that human RASD2 mRNA is abundant in putamen, but it also occurs in the cerebral cortex, with a distinctive expression pattern that differs from that present in rodents. Consistent with its localization, we found that a genetic variation in RASD2 (rs6518956) affects postmortem prefrontal mRNA expression in healthy humans and is associated with phenotypes of relevance to schizophrenia, including prefrontal and striatal grey matter volume and physiology during working memory, as measured with magnetic resonance imaging. Interestingly, quantitative real-time PCR analysis indicated that RASD2 mRNA is slightly reduced in postmortem prefrontal cortex of patients with schizophrenia. In the attempt to uncover the neurobiological substrates associated with Rasd2 activity, we used knockout mice to analyze the in vivo influence of this G-protein on the prepulse inhibition of the startle response and psychotomimetic drug-related behavioral response. Data showed that Rasd2 mutants display deficits in basal prepulse inhibition that, in turn, exacerbate gating disruption under psychotomimetic drug challenge. Furthermore, we documented that lack of Rasd2 strikingly enhances the behavioral sensitivity to motor stimulation elicited by amphetamine and phencyclidine. Based on animal model data, along with the finding that RASD2 influences prefronto-striatal phenotypes in healthy humans, we suggest that genetic mutation or reduced levels of this G-protein might have a role in cerebral circuitry dysfunction underpinning exaggerated psychotomimetic drugs responses and development of specific biological phenotypes linked to schizophrenia.

Indexed as

Schizophrenic PsychologyAdolescentAdultAnimalsCorpus StriatumDisease Models, AnimalFemaleGTP-Binding ProteinsHumansMaleMice, Inbred C57BLMice, KnockoutMiddle AgedPhenotypePolymorphism, Single NucleotidePrefrontal CortexGTP-Binding ProteinsRASD2 protein, humanRasd2 protein, mouseRNA, Messenger

Identifiers

PMID26228524
PMCPMC4707838
OpenAlexW2414029203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.